Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMML201 azacitidine phase 2 study in chronic myelomonocytic leukemia
2008-006349-23Phase 2Completed
- Sponsor
- Leeds Teaching Hospitals NHS Trust
- Start
- Apr 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in chronic myelomonocytic leukemia (CMML), sponsored by Leeds Teaching Hospitals NHS Trust. Primary endpoint: Safety and tolerability of azacitidine. Started Apr 2009; status: completed.
02
Drugs
azacitidine
03
Conditions
chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on 2008-006349-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006349-23.